Long-term prospects of therapy with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
https://doi.org/10.62751/2713-0177-2025-6-1-05
Abstract
Currently, dipeptidyl peptidase-4 inhibitors (gliptins) consistently occupy an increasingly important place in the arsenal of endocrinologists worldwide and are considered one of the most promising classes of hypoglycemic agents. According to the results of numerous studies among representatives of this group, vildagliptin demonstrates the greatest efficacy and safety in the treatment of type 2 diabetes mellitus, which, in addition to its sugar-lowering effect, has a positive effect on the cardiovascular system in the long term, has a beneficial effect on blood pressure, exhibits cardioprotective properties, is well tolerated by patients and has a low risk of hypoglycemia. These characteristics allow us to recommend vildagliptin for the treatment of patients with a wide range of comorbidities, including the elderly and senile.
About the Author
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana Yu. Demidova – MD, Dr. Sci. (Med.), prof., hed of the Department of endocrinology
Scopus Author ID: 7003771623
Moscow
References
1. Аракелянц А.А., Горохова С.Г. Поражение сердца при сахарном диабете. Российский кардиологический журнал. 2004; 9 (1): 80–86.
2. Ушанова Ф.О., Демидова Т.Ю., Часовская Ю.С. Интенсивный старт в современной стратегии управления сахарным диабетом 2 типа: фокус на оригинальные ингибиторы дипептидилпептидазы-4. FOCUS Эндокринология. 2024; 5(3): 72–77. doi: 10.62751/2713-0177-2024-5-3-09.
3. Демидова Т.Ю., Ушанова Ф.О. Роль и место ингибиторов дипептидилпептидазы-4 в современных подходах к ведению сахарного диабета 2 типа. Терапия. 2023; 9(9): 117–124. doi: 10.18565/therapy.2023.9.117-124.
4. Моргунов Л.Ю. Вилдаглиптин: известное и неизвестное. Медицинский совет. 2016; (3): 92–97. doi: 10.21518/2079-701X-2016-3-92-97.
5. Аметов А.С. Патофизиологический подход как основа выбора стратегии успешного лечения сахарного диабета 2 типа. Фарматека. 2017; (5): 3–9.
6. Бирюкова Е.В. Вилдаглиптин в клинической практике: анализ сравнительных исследований лекарственных средств с инкретиновой активностью. Сахарный диабет. 2014; (1): 81–84. doi: 10.14341/DM2014181-84.
7. Chan JCN, Paldanius PM, Mathieu С et al. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: A subanalysis of the VERIFY study. Diabetes Obes Metab. 2021; 23(1): 245–51. doi: 10.1111/dom.14192.
8. Matthews DR, Paldanius PM, Proot P et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208): 1519–29. doi: 10.1016/S0140-6736(19)32131-2.
9. Evans M, Kozlovski P, Paldanius PM et al. Factors that may account for cardiovascular risk reduction with a dipeptidyl peptidase-4 inhibitor, vildagliptin, in young patients with type 2 diabetes mellitus. Diabetes Ther. 2018; 9(1): 27–36. doi: 10.1007/s13300-017-0329-5.
10. McInnes G, Evans M, Del Prato S et al. Cardiovascular and heart failure safety profile of vildagliptin: A meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015; 17(11): 1085–92. doi: 10.1111/dom.12548.
11. Emerging Risk Factors Collaboration; Di Angelantonio E, Gao P, Khan H et al. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014; 311(12): 1225–33. doi: 10.1001/jama.2014.1873.
12. White WB, Kupfer S, Zannad F et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care. 2016; 39(7): 1267–73. doi: 10.2337/dc16-0303.
13. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011; 34 Suppl 2 (Suppl 2): S101–6. doi: 10.2337/dc11-s202.
14. Wicinski M, Gorski K, Wodkiewicz E et al. Vasculoprotective effects of vildagliptin. Focus on atherogenesis. Int J Mol Sci. 2020; 21(7): 2275. doi:10.3390/ijms21072275
15. Noguchi K, Hirota M, Miyoshi T et al. Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med. 2015; 9(1): 84–88. doi: 10.3892/etm.2014.2051.
16. Wang J, Wu HY, Chien KL. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes. Diabetes Metab. 2022 May;48(3):101299. doi: 10.1016/j.diabet.2021.101299.
17. Tani S, Takahashi A, Nagao K., Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J Cardiol. 2015; 115(4): 454–60. doi: 10.1016/j.amjcard.2014.11.044.
18. Evans M, Schweizer A, Foley J.E. Blood pressure and fasting lipid changes after 24 weeks’ treatment with vildagliptin: A pooled analysis in >2,000 previously drugnaïve patients with type 2 diabetes mellitus. Vasc Health Risk Manag. 2016; 12: 337–40. doi: 10.2147/VHRM.S112148.
19. Guo W-Q, Li L, Su Q et al. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A network meta-analysis. Value Health. 2017; 20(10): 1427–30. doi: 10.1016/j.jval.2017.04.010.
20. Саприна Т.В., Файзулина Н.М. Сахарный диабет 2 типа у лиц пожилого возраста – решенные и нерешенные вопросы. Сахарный диабет. 2016; 19(4): 322–330. https://doi.org/10.14341/DM7884.
21. Avogaro A, Dardano A, de Kreutzenberg SV, Del Prato S. Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. Diabetes, Obesity and Metabolism. 2014; 17(2): 107–15. https://doi.org/10.1111/dom.12319.
22. Lu F-P, Lin K-P, Kuo H-K. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLOS One. 2009; 4(1): e4144. doi: 10.1371/journal.pone.0004144.
23. Whitmer RA, Karter AJ, Yaffe K et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301(15): 1565–72. doi: 10.1001/jama.2009.460.
24. Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, doubleblind, randomized trial. Diabetes, Obes Metab. 2009; 11(8): 804–12. doi: 10.1111/j.1463-1326.2009.01051.x.
Review
For citations:
Demidova T.Yu. Long-term prospects of therapy with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus. FOCUS. Endocrinology. 2025;6(1):37-42. (In Russ.) https://doi.org/10.62751/2713-0177-2025-6-1-05
Views:
84
Email this article 